Clinical Trial Update: Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating pepinemab in combination with pembrolizumab in recurrent or metastatic head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Pepinemab (pepinemab)

Snippet

Sponsor: Vaccinex Inc. | Conditions: Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) | Phase 1, Phase 2 | Status: COMPLETED